There is a rebuttal from the author which you should post also.
Again the NME issue is made up by dam and his continued insistence to bring it up after being proven 100% false really makes his credibility almost zero related to AMRN. Add in his statement that the launch would be delayed past Q1 and several other items he's been inaccurate on almost all details. Yes, he is a bear and yes the stock is down so he has had the right trend but that story is still being written and reading his comments and articles anything that can be factually checked later he is batting pretty much zero on AMRN. I can;t actually find anything factually related to the company that he actually got right in hindsight.
Vascepa initial sales were lower than most anticipated but the trend is as expected since then. I see no reason to believe 2014 total sales are not 500 million, when you analyze all the info that seems a pretty easy goal to reach. They will be running 100 million annual basis by end of year and then adding 10 times the market and 5 times the sales people. 1.5 billion should be minimum peak sales though so much of that depends on REDUCE IT but they should eb at 1.5 billion before full REDUCE IT results which will either cut sales in half or multiply them by 10.
Using 6 times sales or 3 times peak sales gets you 3-4.5 billion by end of 2014 in market cap or in the range of 2-4 times current price. Of course the launch of Anchor could dilute the stock or reduce AMRN's ownership of Vascepa but they also get a return on that so should be a wash to market cap.
News 
Market Data 
Discover 
